ArticlePatient preference and adherence2025
Perspectives of Chinese Adult Patients with Alopecia Areata on Janus Kinase Inhibitors Therapy: A Qualitative Analysis Based on Social Media Platforms.
Article in Patient preference and adherence, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Alopecia areata (AA) is a common autoimmune disorder causing non-scarring hair loss. Janus kinase (JAK) inhibitors have emerged as a promising new treatment approach for AA. This study aimed to investigate the perspectives of Chinese adult AA patients on JAK inhibitor therapy through a qualitative analysis of social media discussions. Methods: Keyword searches were conducted on two major Chinese social media platforms, Bidu and Sina Weibo, to retrieve AA-related discussion posts within China. A total of 300 posts met the inclusion criteria and were analyzed using natural language processing techniques. All data used in this study were publicly available, anonymized, and obtained without interaction with human subjects, ensuring compliance with ethical standards. High-frequency terms were categorized into four main themes: drug information, efficacy and side effects, shared experiences, and treatment choices. Results: Tofacitinib and baricitinib were the most frequently mentioned JAK inhibitors. Patients' discussions focused on treatment efficacy, relapse after discontinuation, and side effects. Specific attention was given to treatment effects at different time points. The psychological burden and emotional impact of AA emerged as significant themes in patients' shared experiences. Patients' discussions on treatment choices and brand selection reflected their active involvement in decision-making and desire for personalized treatment options. Conclusion: This study reveals the significant interest and hope that Chinese adult AA patients have in JAK inhibitor therapy. The findings underscore the importance of comprehensive patient education, individualized risk assessment, and shared decision-making in the management of AA. Understanding patients' perspectives is crucial for developing patient-centered care strategies and improving treatment outcomes. Previous studies have demonstrated the feasibility and value of using social media data to explore patient perceptions and health behaviors in various diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.